Biogen Earnings Call Signals Confident, Investment-Heavy Transition

Biogen Inc. ((BIIB)) has held its Q1 earnings call. Read on for the main highlights of the call.

Biogen’s latest earnings call struck a cautiously optimistic tone, as management balanced strong EPS growth, expanding growth-product revenue, and a deepening pipeline against near-term volatility from inventory timing, higher R&D and SG&A spending, and sizable acquired R&D charges. Executives emphasized confidence in execution, cash generation, and the strategic logic of the Apellis deal, even as they acknowledged regulatory and competitive risks ahead.

Solid Q1 performance and stronger earnings power

Biogen reported Q1 revenue of $2.5 billion, up 2% year over year, with GAAP diluted EPS rising 31% to $2.15 and non-GAAP EPS up 18% to $3.57. The company generated $594 million in free cash flow, ending the quarter with $4.7 billion in cash and marketable securities and net debt of $1.5 billion, underscoring a strengthened balance sheet.

Growth products now outpace legacy MS portfolio

Growth products delivered $851 million in Q1 revenue, increasing 12% year over year and for the first time surpassing the rest of the multiple sclerosis portfolio. This shift marks a key inflection in Biogen’s mix, as newer therapies increasingly offset declines in mature MS products and anchor the company’s transition toward diversified growth.

LEQEMBI shows rapid uptake and durable usage

LEQEMBI generated $168 million in Q1 revenue, up 74% year over year, and continues to lead by total patient share in the U.S., Japan, and China. Real-world persistence remains high at roughly 80% at 18 months and about 70% at two years, and a late-May regulatory decision on IQLIK initiation could further enhance convenience and competitive positioning.

SKYCLARYS expands globally despite U.S. lumpiness

SKYCLARYS posted $151 million in Q1 revenue, up 22% from a year ago, with availability now in 35 countries and solid sequential patient growth outside the U.S. Management highlighted slower and lumpier U.S. uptake due to challenging patient-finding dynamics and an older, slower-progressing population, requiring more time and targeted field efforts.

High-dose SPINRAZA launch gains early traction

High-dose SPINRAZA secured approvals in the U.S., Japan, and Europe, with early patient starts already underway across regions. Biogen cited encouraging anecdotal evidence of switches and back-switches, including early German data pointing to roughly 20% conversion in the initial launch phase, supporting confidence in the higher-dose strategy.

Pipeline advances and a busy readout runway

The pipeline advanced on several fronts, including one-year durability data for Salanersen in previously gene-therapy treated children and first patient dosing in the pivotal STELLA-1 study. Biogen also reported positive Phase II results for Litifilimab in SLE and CLE and pointed to a multiyear flow of registrational data beginning in 2026, with multiple Phase III readouts expected through the decade.

Apellis deal to broaden portfolio and lift EPS

The proposed acquisition of Apellis, adding SYFOVRE and Empaveli, is aimed at expanding Biogen’s immunology and rare disease footprint while lifting long-term earnings power. The transaction is expected to be accretive to non-GAAP EPS in 2027, with funding coming from about $3.6 billion in cash plus $2 billion in borrowings that management plans to repay by the end of 2027.

Felzartamab strengthens nephrology ambitions

Biogen added to its nephrology franchise by acquiring China rights to felzartamab through the TJ Bio transaction, signaling growing conviction in this asset. Management sees significant potential in antibody-mediated rejection and IgA nephropathy, with key Phase III readouts anticipated and a meaningful commercial opportunity in nephrology emerging over time.

Cost discipline paired with stepped-up investment

Non-GAAP core operating expenses were about $1.1 billion in Q1, as Biogen kept a disciplined cost posture while ramping investment in late-stage programs and launches. The company highlighted that targeted R&D and commercial spending, including prelaunch and marketing initiatives, is designed to secure long-term growth even if it weighs on near-term margins.

Cash generation supports flexible capital deployment

With $594 million of free cash flow in the quarter and a sizable cash position, Biogen emphasized its ability to fund both internal projects and external deals. Management underlined that strong expected cash flow should allow the company to invest in the business, execute on the Apellis transaction, and still prioritize deleveraging over the next few years.

Modest top-line growth masks underlying transition

Total revenue growth of just 2% year over year underscores that Biogen remains in a modest top-line phase as legacy products decline. However, management framed this as a transition period in which emerging growth franchises, alongside new launches, are gradually stabilizing and repositioning the company for more durable expansion.

Timing and inventory create revenue volatility

SPINRAZA revenue dipped slightly due to shipment timing and a one-time VAT item, rather than underlying demand erosion, according to management. SKYCLARYS U.S. revenue was also affected by inventory dynamics and fewer buying weeks in Q1, leading executives to stress that quarter-to-quarter results can appear lumpy.

Acquired R&D charges weigh on near-term EPS

Biogen recorded about $34 million of acquired IPR&D in Q1, equating to roughly $0.20 per share, and expects around $145 million in Q2, or about $0.80 per share. These charges, tied to deals such as TJ Bio and the Salanersen milestone, create short-term EPS pressure but are framed as strategic investments in future growth.

Higher R&D and SG&A spending pressures margins

Non-GAAP R&D spending reached $480 million and SG&A $600 million, both up year over year as Biogen funds Phase III programs, prelaunch efforts, and broader marketing including direct-to-consumer campaigns. Management acknowledged that these elevated expenses could compress margins in the near term but views them as necessary to support multiple upcoming product waves.

Key regulatory and scientific risks remain

Several binary events loom, including the LEQEMBI subcutaneous induction decision, which could materially influence the drug’s convenience and uptake. Pioneering programs such as BIIB080, a tau-targeting antisense therapy, still face uncertainty over whether biomarker gains will translate into cognitive benefit, and the program has already been downsized, reflecting scientific risk.

Short-term leverage and financing costs from Apellis

The Apellis deal will introduce about $2.0 billion in bank borrowings, temporarily increasing Biogen’s leverage and financing burden. Management expects a roughly $120–130 million impact to 2026 non-GAAP other income and expense from financing and foregone interest, though they plan to neutralize this by repaying the new debt by 2027.

Forward guidance emphasizes 2026 trajectory and Apellis impact

Biogen reaffirmed its underlying 2026 outlook, pointing to about $600 million in contract manufacturing revenue that will be weighted roughly two-thirds in the first half of the year. The company expects Q2 core operating expenses to be roughly in line with Q1, anticipates about $145 million of acquired IPR&D in Q2, and reiterated that the Apellis transaction, projected to close in Q2, should be accretive to non-GAAP EPS in 2027 despite a modest 2026 financing drag.

Biogen’s earnings call portrayed a company in active transition, using strong cash flow and selective deal-making to build a broader growth platform while absorbing near-term volatility and higher investment. For investors, the story hinges on continued execution in Alzheimer’s, rare disease, and ophthalmology, alongside successful integration of Apellis and delivery on a crowded late-decade readout calendar.